Charles River Laboratories International, Inc. (CRL) Fair Value 2026

CRL · Diagnostics & Research ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.9 /10

32 fundamental signals · 8 models active

Value Trap Risk

WARN (43/100)

Quick Summary — As of 2026-08-27, Charles River Laboratories International, Inc. (CRL) trades at $296.41, versus a $110.86 median fair value across its 8 active models — 62.6% below the current price. QOC: 6.9/10. Value Trap Risk: 43/100 (WARN). 8/13 models active. Within that set, the Bayesian DCF component alone returns $121.90.

Key Facts

Ticker
CRL
Price
$296.41
Quality Score
6.9/10
Value Trap Risk
43/100
Models Active
8/13
Last Updated
Strength: 8 independent models provide multi-angle coverage
Risk: Value Trap score of 43 suggests caution despite apparent undervaluation

Is Charles River Laboratories International, Inc. (CRL) Undervalued or Overvalued in 2026?

According to CirclFi’s 8-model valuation engine, Charles River Laboratories International, Inc. (CRL) appears overvalued as of : the median of 8 independent fair value estimates is $110.86, 62.6% below the current price of $296.41. Estimates range from $30.47 to $410.21. CRL scores 6.9/10 on fundamental quality and 43/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. CRL’s -62.6% gap is wider than that market norm, and the Diagnostics & Research sector median is -54.1%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Charles River Laboratories International, Inc. Stock in 2026? →

What Fair Value Does Each Model Give CRL?

8 Intrinsic Value Models vs. Current Price ($296.41)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $121.90 -58.9%
Intrinsic · High Conviction
 $30.47 -89.7%
Ensemble · Low Conviction
 $104.70 -64.7%
Intrinsic · High Conviction
 $36.18 -87.8%
Unlock the Full Matrix

Access 4 additional models including Regime Cross-Sectional, Sentiment SOTP, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 8 Models →

Cancel anytime · No contracts · Instant access

What Is CRL's Fair Value Range?

Spread across 8 independent models · $30.47 to $410.21

CirclFi's 8 active models place Charles River Laboratories International, Inc. (CRL) between $30.47 and $410.21 per share, a spread of 343% of the median. The median of that range — $110.86 — is the fair value CirclFi publishes for CRL, against a current price of $296.41.

Low · EPVHigh · Regime Cross
$30.47median $110.86$410.21
Where the range comes from
Most bearish modelEarnings Power Value (EPV)$30.47
Most bullish modelRegime Cross-Sectional$410.21
Model agreement1 bullish · 7 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for CRL. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on CRL, not a CirclFi price target. How each model works →

What Is Charles River Laboratories International, Inc. (CRL) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Charles River Laboratories International, Inc.'s intrinsic value is estimated at $110.86, suggesting the stock is overvalued at its current price of $296.41. With 7 out of 8 models flagging downside (-62.6% vs price), the market may be pricing in unsustainable growth. The most optimistic model, Regime Cross, places fair value at $410.21 (+38.4%), while EPV — the most conservative — estimates $30.47 (-89.7%). This +128.1% gap reflects genuine analytical uncertainty about Charles River Laboratories International, Inc.'s intrinsic worth. Among models with highest confidence, EPV lean bearish — adding weight to the bearish side of the thesis.

What Do the Models Say About CRL?

8 of 13 models are currently active for CRL. Of these, 1 model suggests upside while 7 models suggest overvaluation. Taken together, their median fair value for CRL is $110.86 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $121.90 on its own, implying -58.9% downside from the current price. See which stocks rank higher →

How Does CRL Rank in Diagnostics & Research?

Among 52 Diagnostics & Research stocks, CRL ranks #25 by Quality of Company score. CirclFi's QOC score of 6.9/10 evaluates 32 fundamental signals. A score of 6.9 indicates above-average quality.

As a pharmaceutical industry, Charles River Laboratories International, Inc. operates in a sector where clinical trial success rate is a critical driver of valuation. Investors evaluating CRL should weigh these sector-specific dynamics alongside our model-derived fair values.

Is CRL a Value Trap?

CirclFi's Value Trap algorithm assigns CRL a score of 43/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

8 of 13 models are active for Charles River Laboratories International, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Charles River Laboratories International, Inc. is rated at 6.9/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.

The gap between the most bullish and bearish model spans +128.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CRL valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across CRL's 8 active models, average confidence is 47%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Charles River Laboratories International, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Diagnostics & Research Stocks Should You Also Analyze?

11 related Diagnostics & Research stocks with 13-model coverage

FLGTFulgent Genetics, Inc.QOC 7.0PRPOPrecipio, Inc.QOC 6.7GHGuardant Health, Inc.QOC 7.0XGNExagen Inc.QOC 6.7ADPTAdaptive Biotechnologies CorporationQOC 7.2RDNTRadNet, Inc.QOC 6.7QUCYQuantum Cyber N.V.QOC 5.6MBAIMBody AI Corp.QOC 2.5TMOThermo Fisher Scientific Inc.QOC 7.8IDXXIDEXX Laboratories, Inc.QOC 9.5MEDPMedpace Holdings, Inc.QOC 9.3

Read investment analysis: FLGT · PRPO · GH · XGN · ADPT · RDNT · QUCY · MBAI · TMO · IDXX · MEDP

Which Other Stocks Have a Similar Quality Score to CRL?

7 companies across all industries closest to CRL’s Quality of Company score of 6.9/10.

SMWBSimilarweb Ltd.QOC 6.9VMRKAvalonBay Communities, Inc.QOC 6.9KRMNKarman Holdings Inc.QOC 6.9NRIXNurix Therapeutics, Inc.QOC 6.9FWRGFirst Watch Restaurant Group, Inc.QOC 6.9DDDuPont de Nemours, Inc.QOC 6.9NVDANVIDIA CorporationQOC 10.0

Read investment analysis: SMWB · VMRK · KRMN · NRIX · FWRG · DD · NVDA

What Else Do Investors Ask About Charles River Laboratories International, Inc.’s Valuation?

What is Charles River Laboratories International, Inc.'s intrinsic value in 2026?

CirclFi puts Charles River Laboratories International, Inc. (CRL)'s intrinsic value at $110.86 — the median of 8 independent model estimates as of 2026-08-27, ranging from $30.47 to $410.21. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $121.90 on its own. The Quality of Company score is 6.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CRL overvalued or undervalued right now?

At $296.41, 1 of 8 active models suggest CRL may be undervalued, while 7 indicate potential overvaluation. The median of all 8 fair value estimates is $110.86, 62.6% below the current price of $296.41 — a consensus view that CRL is overvalued. The assessment depends on which methodology best fits Charles River Laboratories International, Inc.'s business model in Diagnostics & Research.

What does a Quality of Company score of 6.9 mean for CRL?

Charles River Laboratories International, Inc.'s QOC of 6.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on CRL?

CirclFi analyzes CRL with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 8 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on CRL?

Of the 8 models currently active on CRL, Regime Cross-Sectional is the most bullish at $410.21 per share, and Earnings Power Value (EPV) is the most bearish at $30.47. CirclFi's published fair value for CRL is the median of that range, $110.86, not either extreme. The gap between the two ends equals 343% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is CRL a value trap in 2026?

Charles River Laboratories International, Inc.'s Value Trap score is 43/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries.

Cite this analysis — “According to CirclFi’s 8-model valuation engine, Charles River Laboratories International, Inc. (CRL) has a median fair value of $110.86 — 62.6% below the current price of $296.41 — as of 2026-08-27.” Source: circlfi.com/stock/CRL/ · Methodology
Primary sources for this CRL valuation

Market data for CRL as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 8 mathematical frameworks give you clarity on CRL.

Unlock All 8 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

4 models hidden for CRL Unlock All 8 — $39/mo